Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines
- 1 March 2007
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Cardiovascular Medicine
- Vol. 4 (3) , 151-162
- https://doi.org/10.1038/ncpcardio0823
Abstract
Approximately one-third of patients with diabetes have peripheral arterial disease (PAD) and concomitant diabetes amplifies the already high risk of atherothrombotic events present in those with PAD. Here, Emile R Mohler III discusses atherothrombosis and PAD in patients with diabetes in the context of the 2006 American College of Cardiology/American Heart Association guidelines for PAD management. The increased risk of atherothrombotic events present in all patients with peripheral arterial disease (PAD) is amplified with concomitant diabetes. Moreover, diabetes is associated with increased PAD severity. This Review summarizes atherothrombosis and PAD in patients with diabetes, and American College of Cardiology and American Heart Association guidelines for management of patients with PAD. Patients with PAD and diabetes require optimal limb care and aggressive cardiovascular risk reduction. An LDL cholesterol level of less than 1.8 mmol/l (<70 mg/dl) is the therapeutic goal in these patients, and this target should be pursued using an aggressive statin regimen. Fibrate therapy can also be indicated. β-blockers and angiotensin-converting-enzyme inhibitors reduce cardiovascular events in high-risk patient populations, and these agents are recommended for use in patients with both diabetes and PAD. Blood pressure of less than 130/80 mmHg should be achieved, and glycated hemoglobin should be reduced to below 7%. Patients should also receive indefinite antiplatelet therapy with aspirin or clopidogrel. For patients with claudication, a supervised exercise program and cilostazol therapy to improve PAD symptoms and walking distance form the main noninvasive components of therapy. Revascularization can also be indicated in carefully selected patients with claudication. For patients with critical limb ischemia, diagnostic testing by a vascular specialist will determine whether revascularization or amputation is feasible.Keywords
This publication has 59 references indexed in Scilit:
- Low Ankle-Brachial Pressure Index Predicts Increased Risk of Cardiovascular Disease Independent of the Metabolic Syndrome and Conventional Cardiovascular Risk Factors in the Edinburgh Artery StudyDiabetes Care, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialPublished by Elsevier ,2005
- Relation of Inflammation to Peripheral Arterial Disease in the National Health and Nutrition Examination Survey, 1999–2002The American Journal of Cardiology, 2005
- The annual incidence of diabetic complications in a population of patients with Type 1 and Type 2 diabetesDiabetic Medicine, 2005
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996